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on the impact of beta-blocking agents on postinfarction remodeling, 
but those that are available (2,3) suggest that these agents can 
impede myocyte hypertrophy after infarction and can induce regres- 
sion of established increases in ventricular mass. Fishbein and 
colleagues (2) demonstrated that propranoloi therapy attenuated 
myocyte hypertrophy after infarction i  the rat and resulted in 
increased left ventricular cavity dimensions, thus suggesting that 
ventricular dilation in this model is not exclusively related to 
myocyte lengthening. Preliminary data from our laboratory have 
demonstrated hat metoproiol can induce regression f established 
increases in both left ventricular mass and end-diastolic volume ina 
canine model of localized myocardiai necrosis (3). in this same 
model we have also demonstrated hat oral nitrates are effective in
blocking the increase in left ventricular mass and end-diastolic 
volume observed in untreated animals (4). In contrast o the 
observations of Rumberger t al. (S), myocardiai mass does increase 
in the dog after regional myocardial damage, and Ginzton and 
colleagues (6) provided evidence that ventricular mass increases 
following infarction i humans. 
The issue of sequential changes inmyocardiai mass and ventric- 
ular voiun?e after infarction in humans i of considerable impor- 
tance. Data B;e seeded in patients who have not been treated with 
drugs that may interfere with the normal process ofhypertrophy and 
remodeling, 
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Rep& 
McDonald and Cohn point out that pharmacologic therapy pre- 
scribed after myocardiai nfarction must be considered in discussing 
observed cardiac anatomic and physiologic adaptations. Beta- 
adrenergic therapy or use of long-acting itrates, or both, is com- 
monly prescribed during the 1st year after myocardiai nfarction to 
limit or prevent ischemia, rrhythmia or reinfarction a d was done 
in our study at the discretion of the attending cardiologist. This 
factor epresents a limitatian of the study regarding the “natural 
history” of postinfarction ventricular remodeling, but it may reflect 
a ChiCal situation commoniy seen tier noncomplicated infarction. 
We showed a decrease in global ventricular muscle mass during 
the 1st 6 weeks after infarction, whereas chamber volumes remained 
unchanged in patients with a small inferior wail infarction and 
increased significantly in patients with a moderately large anterior 
wall infarction. However, from 6 weeks to 1 year after infarction, 
there was a clear but nonsignificant trend (in this limited sample 
population) toward what may be suggestive of ventricular hyper- 
trophy. Our contention is that ieft ven!ricuiar remodeling after 
infarction behaves as a volume overload situation and in some 
patients i  associated with early ventricular enlargement that may be 
progressive. L ft ventricular hypertrophy in the noninfarcted myo- 
cardium occurs 2s a “reactive” type of hypertrophy. However, it 
occurs with a significant time lag to the early ventricular dilation and 
may be insufficient to limit increases in ventricular wail stresses (1). 
We do not agree, however, that concomitant therapy with 
nitrates and beta-blockers limits these conclusions. The cited study 
by Ginzton et al. (2) demonstrated increases inventricular muscle 
mass in 46 patients between 6 and 40 weeks after myocardiai 
infarction. Patients taking a beta-adrenergic blocking agent had 
increases in left ventricular mass index similar to those of patients 
not taking abeta-blocking agent. This observation is in contrast to 
the sggestion of McDonald and Cohn that beta-blockade limits the 
development of hypertrophy. In contrast to our study, however, 
patients inthe study of Gin&on et al. were not excluded if they bad 
a prior infarction orcompensated congestive h art failure, and there 
were no data on concomitant changes inventricular cavity volumes. 
Our observations i  patients show ventricular enlargement after 
infarction and delayed onset of ventricular hypertrophy. In contrast, 
canine studies by McDonald and colleagues (3-5) using the trans- 
myocardiai shock method have shown development of left ventric- 
ular hypertrophy within I week of infarction but little or no change 
in global chamber volumes until many weeks after infarction. 
Regardless of these inconsistencies, McDonald and Cohn have 
shown that left ventricular hypertrophy can be prevented or limited 
or can regress after infarction with use of angiotensin-converting 
enzyme inhibitors (4), beta blockers (4) and nitrates (5). 
The data from our study reflect changes from baseline measure- 
ments made at 1 week to approximately 52 weeks after infarction but 
are not sufficiently complete oallow firm conclusions 2s to whether 
some hypertrophy ad already occurred uring the 1st week. The 
canine studies noted examined ventricular volumes and muscle 
mass at a preinfarction baseline and then at short- and long-term 
intervals after infarction. In their serial study of control animals, 
McDonald and Cohn (3) found little change in total eft ventricular 
muscle mass from I week to 6 months after infarction (despite 
elevation i muscle mass compared with the level at preinfarction 
baseline) followed by a clear (nonsignificant) trend toward hyper- 
trophy from 6 months to 1 year. The data re not inconsistent with 
our observations a  discussed here. Additionally, ina companion 
study, under control conditions, McDonald and Cohn (5) noted 
ventricular cavity enlargement at 16 weeks compared with measure- 
ments 1week after infarction, but there was no additional increase 
in left ventricular musde mass from I week to 16 weeks in this same 
animal subgroup. 
In summary, we agree that here may be evidence that concom- 
itant herapy with nitrates or beta-blockers, or both, may alter or 
impede the development of left ventricular hypertrophy after infarc- 
tion. Additionally, there is no question that ventricular hypertrophy 
(and ventricular dilation) can develop remote from the time of 
infarction. However, these facts do not detract from our conclusions 
that, in patients, changes inventricular chamber volumes and left 
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ventricular cavity muscte mass during the 1st year after an in 
myocardial infarction occur in a nonparallel fashion. The observa- 
tions, in fact, are vindicated by prior ex 
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We congratulate Yeung-kai-Wab and colleagues (1) fc~r their in&z- 
esting report concerning combination drug therapy usiaag pro- 
pafenone (a class IC antiarrhythmic agent) and mexiletine (a class I
agent) in patients with a history of sustained ventricular tachycardia 
that had not responded to propafenone or proca~~am~de alone or in 
combination. 
Undoubkdly, the electrophysidogic properties of these antiar- 
rhythmic drugs are partially due to specific interactions with sodium 
channels, as described in the modulated receptor model proposed by 
Hondeghem and Katzung (2). We disagree, however, that “little is 
known about pharmacokinetic interaction between propafenone and 
mexiletine” (I). The metabolism of propafenone (as well as that of 
encainide and flecainide) is genetically mediated, following the same 
oxidation pathway as that of debrisoqnine and sparteine through the 
P450 2 II6 cytochrome (also known as P45Q dbl or CYFED6). It 
follows then that, like debrisoquine, these drugs exhibit genetic 
polymorphism in patients who are either “extensive” or “poor” 
metabolizers (3-6). It has also been demonstrated (7-9) that mexi- 
letine metabolism, both in vitro and in vivo, is probably linked to the 
debrisoquinekparteiae pathway, with similar genetic polymor- 
phism. 
Therefore a combination of the two tested drugs could have a 
synergistic effect not only because of specific electrophysiologic 
properties, but also because of an alteration of the metabolism of 
one or both d.i”rigs, which could tead TV a dramatic increase irt the 
plasma levels of the parent drug and a decrease in the levels of its 
metabolites. The absence of blood level determinations in this study 
makes it impossible for the authors to make any statement concem- 
ing such drug interactions. 
fects, and study of a correiation between blood levels and clinical 
as tn take these consi 
Furthermore, because m&iple studies have ed that mex- 
iletine only significantly prolongs the cycle len the ~~~~ced 
ventricular tachycardia , i? scsolb e argued that the improvement in
antiarrhyth cacy of the tested drugs used in c~mb~~at~on 
ight amainly be linked to an increase in the plas levels of 
propafenone as a consequence of mexiletine compe n for the 
same metabolic pathway. 
As a result of these pharmacokinetic alterations, one might 
observe an increase in eit er !RE e!ectrophysiologic 
side effects of the dmg, or both, with aH the attendant conse- 
quences. 
To avoid unexpected and untoward consequences, the choice of 
a~t~a~byt~mic combinations and the choice of dosage should be 
made with great care, especially when the dnngs in question have a 
common metabolic pathway. 
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We thank Libersa and colleagues for their thoughtful comments. 
The additional information regarding the metabolism of mexiletine 
may be very important o the understanding of the propafenone- 
mexiletine interaction. The potential competition for metabolism 
